MADISON, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Wyeth announced today that the jury in the cases of Paula Falzon v. Wyeth, Melinda Galgoul v. Wyeth, Paula Kraskian v. Wyeth and Vicki Felton-Mallut v. Wyeth in Los Angeles Superior Court found in favor of Wyeth in all four cases.
“We are pleased with the verdicts and believe they were supported by the facts. Wyeth will continue to vigorously defend itself in this litigation,” says Lawrence V. Stein, Senior Vice President and General Counsel, Wyeth.
The trial began on October 21, 2005 before The Honorable Daniel S. Pratt. The plaintiffs alleged heart valve injury from the use of the diet drug Pondimin, a drug once marketed by Wyeth. In accordance with procedures established by the Court, three of these four plaintiffs were selected for this trial group by plaintiffs’ counsel. The plaintiffs were represented by the firms of Williams & Bailey and Blizzard, McCarthy & Nabers of Houston, Texas.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
Wyeth
CONTACT: Media: Douglas Petkus of Wyeth, +1-973-660-5218, or ChristopherGarland of Wyeth Pharmaceuticals, +1-484-865-6323, or Investors: JustinVictoria of Wyeth, +1-973-660-5340
Web site: http://www.wyeth.com/
